TY - JOUR
KW - Data Collection
KW - Databases, Factual
KW - *Delivery of Health Care
KW - Reproducibility of Results
AU - S. Wang
AU - S. Sreedhara
AU - S. Schneeweiss
AD - Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, USA. swang1@bwh.harvard.edu.
Department of Medicine, Harvard Medical School, Boston, MA, USA. swang1@bwh.harvard.edu.
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, USA.
Department of Medicine, Harvard Medical School, Boston, MA, USA.
AN - 36045130
BT - Nat Commun
C2 - PMC9430007 Boehringer Ingelheim, Johnson & Johnson and Novartis Pharmaceuticals for unrelated work. She was supported by NHLBI RO1HL141505 and NIA R01AG053302 during the conduct of this work. E.M.G., L.R.G., and M.G. are employees of and have stock options in Aetion, Inc. D.L.I. and E.P. were former employees of Aetion, Inc. during the implementation of this study. Dr. Patorno was supported by the National Institute on Aging (K08AG055670). She is investigator of an investigator-initiated grant to the Brigham and Women’s Hospital from Boehringer Ingelheim, not related to the topic of the submitted work. J.J.G. received salary support from grants from Eli Lilly and Company and Novartis Pharmaceuticals Corporation to the Brigham and Women’s Hospital and was a consultant to Optum, Inc., all for unrelated work during the conduct of this study. He has since become an employee of Johnson & Johnson. Brian Nosek is Executive Director of the Center for Open Science, a nonprofit technology and culture change organization with a mission to increase openness, integrity, and reproducibility of research. A.B. in an employee of GSK and was at study initiation was an employee of Pfizer. He is a shareholder and hold stock options in GSK and previously held stock and stock options at Pfizer. D.B. is an employee of UCB Pharma. J.M.F. was supported by NHLBI RO1HL141505 during the conduct of this study. She has since become an employee of Optum Epidemiology. M.P.L. was supported by NHLBI F32 HL149256. J.R.R. was a paid consultant to Aetion during the first year of this study for unrelated work. K.B.F. is supported by a senior salary support award from the Fonds de recherche du Québec – santé (Quebec Foundation for Research–Health) and a William Dawson Scholar award from McGill University. David Martin has since become an employee of Moderna. All other authors have no conflict of interest to declare.
DO - 10.1038/s41467-022-32310-3
DP - NLM
ET - 2022/09/01
LA - eng
M1 - 1
N1 - 2041-1723
Wang, Shirley V
Orcid: 0000-0001-7761-7090
Sreedhara, Sushama Kattinakere
Schneeweiss, Sebastian
REPEAT Initiative
RO1HL141505/U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)/
Journal Article
Nat Commun. 2022 Aug 31;13(1):5126. doi: 10.1038/s41467-022-32310-3.
PY - 2022
SN - 2041-1723
EP - 5126
T2 - Nat Commun
TI - Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions
VL - 13
ER -